MedPath

Unilateral TAP Block vs Trocar Insertion Sites Infiltration Anesthesia in Laparoscopic Cholecystectomy

Not Applicable
Completed
Conditions
Biliary Disease
Interventions
Drug: Intravenous patient controlled analgesia
Drug: Transversus abdominis plane block
Drug: local infiltration anesthesia
Registration Number
NCT03543202
Lead Sponsor
Diskapi Yildirim Beyazit Education and Research Hospital
Brief Summary

Laparoscopic cholecystectomy is a commonly performed operation in general surgery practice. Peripheral nerve block methods commonly used for analgesia after this operation are: transversus abdominis plane block (TAP) and trocar insertion sites local anesthetic infiltration anesthesia In this study, we aimed to compare these methods in terms of postoperative analgesia, nausea-vomiting and patient satisfaction

Detailed Description

Patients will be randomly allocated by a computer generated random numbers list into three groups. After general anesthesia induction and intubation patients will receive analgesia according to group allocation. In group TAP (Group T) the transversus abdominis plane block will be commenced with ultrasound guidance while the patients is in the supine position with a subcostal approach using 20 mL 0.25% bupivacaine and 21 G block needle. In group infiltration anesthesia (Group I) the trocar insertion sites will be infiltrated with 20 mL 0.25% bupivacaine: 7 mL for the 10 mm trocar insertion sites and 3 mL for the 5 mm trocar insertion sites. The control group (Group C) will not receive any local anesthetic. All patients will receive rescue analgesia with intravenous patient controlled analgesia with tramadol (20 mg bolus dose and 20 minutes lockout time)

Postoperative pain will be assessed during resting and coughing with a Numeric Pain Scale (NRS) and nausea and vomiting with a Postoperative Nausea Vomiting Score at the postoperative 1, 3, 6, 12. and 24 hours. The amount of tramadol consumed in the postoperative period will be recorded. Patient satisfaction will be assessed with the Likert scale at postoperative 24 hours.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
72
Inclusion Criteria

• Clinical diagnosis of biliary disease

Exclusion Criteria
  • Uncooperative patients
  • Blood coagulation disorders
  • Laparatomy
  • Obesity: body mass index >35
  • Renal failure
  • Hepatic failure
  • Emergency surgery
  • Pregnancy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intravenous patient control analgesiaIntravenous patient controlled analgesiawill not receive any regional anethetic intervention will receive intravenous patient controlled analgesia
Transversus abdominis plane blockTransversus abdominis plane blockwill receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
Transversus abdominis plane blockIntravenous patient controlled analgesiawill receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
Local infiltration anesthesialocal infiltration anesthesiawill receive 20ml bupivacaine for Local infiltration anesthesia and intravenous patient controlled analgesia
Local infiltration anesthesiaIntravenous patient controlled analgesiawill receive 20ml bupivacaine for Local infiltration anesthesia and intravenous patient controlled analgesia
Primary Outcome Measures
NameTimeMethod
Postoperative analgesiaPostoperative day 1

Pain will be assessed with a 11 point numeric rating scale (0-10 whereas 0:no pain; 1-3: mild pain; 4-6: moderate pain and 7-10: severe pain)

Secondary Outcome Measures
NameTimeMethod
Patient satisfactionPostoperative 24 th hour

Satisfaction will be assessed with a 5 point Likert scale (0-4 whereas 0:definitely disagree; 1:slightly agree; 3: agree; 4: strongly agree)

Postoperative nausea and vomiting (PONV)Postoperative 1st hour, 3rd hour, 6th hour, 12th hour and 24th hour

PONV will be assessed with a 5 point PONV intensity scale (1-4 whereas 1:absence of PONV; 2: nausea present, vomiting absent; 3 nausea present, vomiting once; 4: nausea present vomiting twice or more

Trial Locations

Locations (1)

Diskapi Yıldırım Beyazıt EAH

🇹🇷

Ankara, Turkey

© Copyright 2025. All Rights Reserved by MedPath